Publications by authors named "David R Gandara"

100Publications

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice.

Nat Rev Clin Oncol 2020 Sep 11. Epub 2020 Sep 11.

UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-020-0423-xDOI Listing
September 2020

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.

Cancer 2020 Jul 4;126(14):3219-3228. Epub 2020 May 4.

Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383626PMC
July 2020

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.

Am Soc Clin Oncol Educ Book 2019 01 17;39:531-542. Epub 2019 May 17.

4 City of Hope Comprehensive Cancer Center, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_237863DOI Listing
January 2019

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.

Clin Lung Cancer 2019 05 27;20(3):e238-e241. Epub 2018 Dec 27.

Department of Internal Medicine, Division of Hematology/Oncology, UC Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183035
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.015DOI Listing
May 2019

American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions.

J Glob Oncol 2018 09 11;4:1-8. Epub 2017 Aug 11.

Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Doug Pyle, American Society of Clinical Oncology, Alexandria, VA; Eduardo L. Cazap, Sociedad Latinoamericana y del Caribe de Oncología Médica, Buenos Aires, Argentina; Nagi S. El Saghir, American University of Beirut Medical Center, Beirut, Lebanon; Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Boston, MA; Clement Adebayo Adebamowo, Institute of Human Virology, Baltimore, MD; David R. Gandara, University of California Davis Comprehensive Cancer Center, Sacramento, CA; Julie Vose, University of Nebraska Medical Center, Omaha, NE; Sandra L. Wong, Dartmouth-Hitchcock Medical Center, Lebanon, NH; and Peter Yu, Hartford HealthCare, Hartford, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.17.00060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180769PMC
September 2018

In Search of an Oncogene Driver for Squamous Lung Cancer.

JAMA Oncol 2018 09;4(9):1197-1198

University of California Davis Comprehensive Cancer Center, Sacramento.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.0774DOI Listing
September 2018

CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates.

Eur Radiol 2018 Dec 4;28(12):5069-5075. Epub 2018 Jun 4.

Department of Radiology, University of California Davis Medical Center, 4860 Y Street, Suite 3100, Sacramento, CA, 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5492-1DOI Listing
December 2018

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

Lung Cancer 2017 10 31;112:165-168. Epub 2017 Aug 31.

University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.015DOI Listing
October 2017

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Clin Lung Cancer 2018 01 6;19(1):35-41. Epub 2017 Jul 6.

Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Phase I - Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.06.010DOI Listing
January 2018

Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy.

Cancer Treat Res Commun 2017 ;10:21-26

Division of Hematology/Oncology, University of California, Davis Comprehensive Cancer Center, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2016.12.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519297PMC
January 2017

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.

Clin Lung Cancer 2018 01 8;19(1):42-50. Epub 2017 Jun 8.

UC Davis Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.05.019DOI Listing
January 2018

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

Clin Lung Cancer 2017 01 24;18(1):1-4. Epub 2016 Dec 24.

University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304163038
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2016.12.011DOI Listing
January 2017

Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.

Carcinogenesis 2017 03 3;38(3):271-280. Epub 2017 Jan 3.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, California

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgw205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862279PMC
March 2017

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2017 May 21;18(3):281-285. Epub 2016 Nov 21.

Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Davis, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837026PMC
May 2017

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.

Clin Proteomics 2016 27;13:31. Epub 2016 Oct 27.

Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis Medical Center, 4501 X Street, Suite 3016, Sacramento, CA 95817 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12014-016-9132-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084393PMC
October 2016

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.

J Clin Oncol 2016 11;34(31):3717-3718

Jonathan W. Riess, Primo N. Lara Jr, and David R. Gandara, University of California Davis Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.0040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477925PMC
November 2016

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Clin Lung Cancer 2017 01 27;18(1):5-12. Epub 2016 Jun 27.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361177PMC
January 2017

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.

JAMA Oncol 2016 Mar;2(3):300-1

University of Colorado Cancer Center, Aurora.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4920DOI Listing
March 2016

Lung-MAP--framework, overview, and design principles.

Chin Clin Oncol 2015 Sep;4(3):36

Department of Thoracic and Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.09.02DOI Listing
September 2015

Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer.

Cancer Epidemiol Biomarkers Prev 2015 Nov 17;24(11):1716-23. Epub 2015 Aug 17.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633344PMC
November 2015

Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap.

J Clin Oncol 2015 Sep 27;33(26):2839-40. Epub 2015 Jul 27.

University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.9692DOI Listing
September 2015

EGFR tyrosine kinase inhibitors in squamous cell lung cancer.

Lancet Oncol 2015 Aug 5;16(8):872-3. Epub 2015 Jul 5.

University of California Davis, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00126-6DOI Listing
August 2015

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jul;10(7):1099-106

*Division of Biomedical Statistics and Informatics, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota; †Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona; ‡Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; §Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University, Durham, North Carolina; ‖Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, NCIC Clinical Trials Group, Queen' University, Kingston, ON, Canada; #Department of Hematology & Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia; **Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, California; ††Department of Statistics for the Data Center/Operations Office, Japan Clinical Oncology Group Data Center, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan; ‡‡Department of Medical Oncology, Japanese Society of Medical Oncology, Tokyo, Japan; §§Department of Medicine, The University of Chicago Medicine and Biologic Sciences Center, Chicago, Illinois; and ‖‖Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153349
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493926PMC
July 2015

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

J Thorac Oncol 2015 Jul;10(7):974-84

*Ohio State University Medical Center, Columbus, Ohio; †University of California Davis Comprehensive Cancer Center, Sacramento, California; ‡H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; §Comprehensive Cancer Center, Medical University of Vienna General Hospital, Vienna, Austria; and ‖Instituto de Biomedicina de Sevilla, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618296PMC
July 2015

Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Clin Cancer Res 2015 May;21(10):2236-43

Department of Medicine (Medical Oncology) and Pathology, University of Colorado Denver, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862209PMC
May 2015

Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".

J Thorac Oncol 2015 May;10(5):e36

SWOG Statistical Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000515DOI Listing
May 2015

Targeting of MEK in lung cancer therapeutics.

Lancet Respir Med 2015 Apr 20;3(4):319-27. Epub 2015 Mar 20.

Department of Thoracic Oncology, LungenClinic Grosshansdorf; member of the Airway research center north (ARCN) as part of the German Centre for Lung Research (DZL), Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(15)00026-0DOI Listing
April 2015

Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer.

J Thorac Oncol 2015 Oct;10(10):1421-9

*Department of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA; †Department of Internal Medicine, University of Maryland, College Park, MD; ‡Department of Oncology, Lombardi Comprehensive Cancer Center of the Georgetown University, Washington, DC; §Department of Biostatistics, University of California, Davis, CA; ‖Division of Medical Oncology, Swedish Cancer Institute, Seattle, WA; ¶Department of Internal Medicine, Swedish Cancer Institute, Seattle, WA; #Department of Internal Medicine, Comprehensive Cancer Center, University of California, Davis, CA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153351
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000508DOI Listing
October 2015

Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.

Cancer Prev Res (Phila) 2015 May 5;8(5):410-8. Epub 2015 Feb 5.

Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-14-0329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618700PMC
May 2015

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

J Thorac Oncol 2015 Feb;10(2):387-91

*Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; †SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Medicine, Arizona Cancer Center, University of Arizona Tucson School of Medicine, Tucson, AZ; §Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA; ║Fox Chase Cancer Center, Philadelphia, PA; ¶Department of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and #Department of Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304604PMC
February 2015

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.

J Thorac Oncol 2015 Jan;10(1):110-5

*University of California Davis Comprehensive Cancer Center, Sacramento, California; †SWOG Statistical Center and the Fred Hutchinson Cancer Research Center, Seattle, Washington; ‡Humboldt Medical Specialists, Eureka, California; and §Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320001PMC
January 2015

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.

J Cancer Res Clin Oncol 2015 Apr 17;141(4):615-26. Epub 2014 Oct 17.

Comprehensive Cancer Center, University of California, Davis, 4501 X Street, Suite 3016, Sacramento, CA, 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-014-1855-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562434PMC
April 2015

Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.

J Clin Oncol 2014 Aug 7;32(23):2463-70. Epub 2014 Jul 7.

Jeffrey W. Allen, University of Tennessee Health Science Center, Memphis, TN; James Moon, Mary Redman, Southwest Oncology Group Statistical Center, Seattle, WA; Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Karen Kelly, Phillip C. Mack, David R. Gandara, University of California Davis Cancer Center, Sacramento, CA; Hanna M. Saba, Central Illinois CCOP/Cancer Care Specialists of Central Illinois, Effingham, IL; Mohamed K. Mohamed, Moses Cone Health System, Greensboro, NC; and Mohammad Jahanzeb, University of Miami, Miami, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.4109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121504PMC
August 2014

Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis.

Lung Cancer 2014 Aug 6;85(2):264-9. Epub 2014 May 6.

Division of Hematology Oncology, and University of California Davis Comprehensive Cancer Center, UC Davis School of Medicine Sacramento, CA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.04.007DOI Listing
August 2014

Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer.

J Thorac Cardiovasc Surg 2014 Jul 19;148(1):36-40. Epub 2014 Mar 19.

Section of General Thoracic Surgery, University of California, Davis Medical Center, Sacramento, Calif.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2014.03.014DOI Listing
July 2014

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.

J Thorac Oncol 2014 Jan;9(1):18-25

*University of California Davis Comprehensive Cancer Center, †Department of Internal Medicine, Division of Hematology & Oncology, University of California, Davis, School of Medicine, Sacramento, California; ‡Department of General-, Visceral- and Tumor Surgery, University of Cologne, Cologne, Germany; §Response Genetics, Inc., Los Angeles, California; ‖Department of Public Health Sciences, University of California, Davis, Davis, California; ¶Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California; and #formerly Response Genetics, Inc., Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000030DOI Listing
January 2014

Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

J Thorac Oncol 2013 Dec;8(12):1519-28

*Levine Cancer Institute, Charlotte, North Carolina; †SWOG Statistical Center, Seattle, Washington; ‡Yale Cancer Center, New Haven, Connecticut; §Cancer Center of Kansas and Wichita CCOP, Wichita, Kansas; ‖Central Illinois CCOP and Cancer Care Specialists, Decatur, Illinois; ¶University of Colorado Cancer Center, Aurora, Colorado; #University of California Davis Cancer Center, Sacramento, California; and **MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072123PMC
December 2013

FASTACT-2: but don't act too fast.

Lancet Oncol 2013 Jul 17;14(8):684-5. Epub 2013 Jun 17.

University of Colorado Cancer Center, 12801 E 17th Avenue, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70281-XDOI Listing
July 2013

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2013 Jul 28;72(1):85-91. Epub 2013 May 28.

USC/Norris Comprehensive Cancer Center, Oncology, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2171-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779138PMC
July 2013